The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $54.45

Today's change-0.28 -0.52%
Updated July 25 3:02 PM EDT. Delayed by at least 15 minutes.
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $54.45

Today's change-0.28 -0.52%
Updated July 25 3:02 PM EDT. Delayed by at least 15 minutes.

Teva Pharmaceutical Industries Ltd crosses below 125-day moving average

Teva Pharmaceutical Industries Ltd is lower today, dropping (U.S.)$0.28 or 0.52% to (U.S.)$54.45 and crossing below its 125-day moving average. Over the last five days, shares have gained 0.64%, but are down 17.05% for the last year to date. Shares have underperformed the S&P 500 by 16.09% during the last year.

Key company metrics

  • Open(U.S.) $54.50
  • Previous close(U.S.) $54.73
  • High(U.S.) $54.76
  • Low(U.S.) $54.03
  • Bid / Ask(U.S.) $54.44 / (U.S.) $54.45
  • YTD % change-17.05%
  • Volume2,093,155
  • Average volume (10-day)6,446,152
  • Average volume (1-month)5,530,515
  • Average volume (3-month)6,114,463
  • 52-week range(U.S.) $48.01 to (U.S.) $72.31
  • Beta0.85
  • Trailing P/E28.35×
  • P/E 1 year forward10.31×
  • Forward PEG1.97×
  • Indicated annual dividend(U.S.) $1.36
  • Dividend yield2.50%
  • Trailing EPS(U.S.) $1.92
Updated July 25 3:02 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.80%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue4,8104,8814,8234,966
Total other revenue--------
Total revenue4,8104,8814,8234,966
Gross profit2,7912,8472,7712,902
Total cost of revenue2,0192,0342,0522,064
Total operating expense3,6453,9503,8134,304
Selling / general / administrative1,1321,2071,0891,177
Research & development389446361386
Depreciation / amortization11--78
Interest expense (income), net operating--------
Unusual expense (income)105192237543
Other operating expenses, total-117167126
Operating income1,1659311,010662
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax867861313621
Income after tax639612120533
Income tax, total22824919388
Net income636500103539
Total adjustments to net income-66-15----
Net income before extra. items636500103539
Minority interest32-130
Equity in affiliates-6-114-46
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items570485103539
Inc. avail. to common incl. extra. items570485103539
Diluted net income570485103539
Dilution adjustment0000
Diluted weighted average shares920876862859
Diluted EPS excluding extraordinary itemsvalue per share0.620.550.120.63
Dividends per sharevalue per share0.340.340.340.34
Diluted normalized EPSvalue per share0.700.710.301.17